Investigational drug · Phase 3
PLS240
Also called: upacicalcet
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Secondary Hyperparathyroidism, Chronic Kidney Disease (CKD), End-stage Kidney Disease (ESKD).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
3
Any phase or sponsor naming "PLS240"
First trial start
2023
Apr 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PLS240", any sponsor or status.
Conditions studied
As listed on its trial records.
- Secondary Hyperparathyroidism
- Chronic Kidney Disease (CKD)
- End-stage Kidney Disease (ESKD)
- End Stage Kidney Disease
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "PLS240" as an intervention, largest first.
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2Pivotal-lookingCompleted
Pathalys PharmaIndustry
NCT05836220 · 412 participants · Start May 15, 2023 · Primary completion Aug 5, 2025
Drug: PLS240; Placebo and 1 more · For: Secondary Hyperparathyroidism; End Stage Kidney Disease
Sites: Anaheim, California; Chula Vista, California; Escondido, California · 68 sites in all
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1Pivotal-lookingCompleted
Pathalys PharmaIndustry
NCT05832931 · 362 participants · Start Apr 28, 2023 · Primary completion Jul 28, 2025
Drug: PLS240; Placebo and 1 more · For: Secondary Hyperparathyroidism; End-stage Kidney Disease (ESKD)
Sites: Pine Bluff, Arkansas; Anaheim, California; Beverly Hills, California · 68 sites in all
- A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPivotal-lookingNot yet recruiting
Pathalys PharmaIndustry
NCT07890584 · 56 participants (planned) · Start Oct 30, 2026 · Primary completion Feb 22, 2032
Drug: PLS240 · For: Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism
Sites: Buffalo, New York
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Kendrick J, Ketteler M, Wolf M, et al. · J Am Soc Nephrol 2026
- Structural basis of calcium-sensing receptor activation by extracellular modulators.
Zeng X, Liu H, Wang X, et al. · J Zhejiang Univ Sci B 2026
- Elastin calcification during the initial stage of vascular calcification in kl/kl mice is suppressed by the calcimimetic upacicalcet.
Hasegawa T, Yamamoto T, Liu X, et al. · Sci Rep 2026
- Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism.
Koiwa F, Honda D, Akari S, et al. · Ther Apher Dial 2026
- Upacicalcet Preserves Albumin Levels in Patients on Hemodialysis with Secondary Hyperparathyroidism: A post hoc Analysis of a Randomized Trial.
Komaba H, Akari S, Ono Y, et al. · Am J Nephrol 2026
- The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.
Sato E, Urata M, Sato S, et al. · Clin Nephrol 2025
Also in development for Secondary Hyperparathyroidism
- Open-Label Extension PLS240Phase 32 trials
Pathalys Pharma · Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD), End Stage Kidney Disease
- SHR6508Phase 32 trials
Shanghai Hengrui Pharmaceutical Co., Ltd. · Secondary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
- CTAP101Phase 21 trial
OPKO Health, Inc. · CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.